Review: The therapeutic role of RAS blockade in chronic heart failure

@article{Werner2008ReviewTT,
  title={Review: The therapeutic role of RAS blockade in chronic heart failure},
  author={Christian M. Werner and Michael B{\"o}hm},
  journal={Therapeutic Advances in Cardiovascular Disease},
  year={2008},
  volume={2},
  pages={167 - 177}
}
  • C. Werner, M. Böhm
  • Published 2008
  • Medicine
  • Therapeutic Advances in Cardiovascular Disease
Cardiovascular disease represents a continuum that starts with risk factors such as hypertension and progresses to atherosclerosis, end-organ damage, and ultimately to chronic heart failure (CHF) and premature death. Renin-angiotensin system (RAS) blockade with angiotensin converting enzyme (ACE) inhibitors and/or angiotensin II type 1 receptor blockers (ARBs) has turned out to be beneficial at all stages of this continuum. Several mechanisms govern the progression of structural myocardial… Expand
Review Article: Management of Subclinical Ventricular Dysfunction
TLDR
Early identification of ALVD through screening is of paramount importance and control of risk factors and comorbid conditions could slow down progression to overt heart failure. Expand
ACE inhibitors – angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease
TLDR
The role mono- and combined therapy of ACE inhibitors and angiotensin II receptor antagonists play in ischemic heart disease is summarized to improve ideas for developing new formulations with combinations of these drugs in the future. Expand
Cardio-renal syndrome type 1: epidemiology, pathophysiology, and treatment.
One third of heart failure admissions may be complicated by acute kidney injury, resulting in a three-fold increase in length of stay and a greater likelihood of rehospitalization. Cardio-RenalExpand
Renin-angiotensin system overactivation in perivascular adipose tissue contributes to vascular dysfunction in heart failure.
TLDR
PVAT is suggested as a target in the pathophysiology of vascular dysfunction in HF and new perspectives for the treatment of this syndrome are provided. Expand
Diabetic cardiomyopathy: ongoing controversies in 2012
TLDR
There is no specific treatment of diabetic cardiomyopathy that targets its pathophysiological substrate, but various therapeutic options are discussed that include improving diabetic control with both diet and drugs (metformin and thiazolidinediones), the use of ACE inhibitors, beta blockers, and calcium channel blockers. Expand
Local angiotensin II aggravates cardiac remodeling in hypertension.
TLDR
Cardiac ANG II does not alter heart size or cardiac functions when hemodynamic loading conditions remain unchanged, however, in animals with hypertension, cardiac ANG II enhances inflammation, oxidative stress, and cell death (most likely via downregulation of PI 3-kinase and Akt), contributing to cardiac hypertrophy and fibrosis. Expand
Diabetic cardiomyopathy--a distinct disease?
TLDR
Future clinical and experimental studies of accurate models of diabetic cardiomyopathy should help to define the true aetiology and lead to the development of specific pharmacotherapies for this condition, ultimately reducing the increased cardiovascular morbidity and mortality in diabetic patients. Expand
Aldosterone promotes atrial fibrillation.
TLDR
Aldosterone causes a substrate for atrial arrhythmias characterized by atrial fibrosis, myocyte hypertrophy, and conduction disturbances, which may have therapeutical impact for primary and secondary prevention of AF. Expand
Innate immune response in the pathogenesis of heart failure in survivors of myocardial infarction.
TLDR
This review presents short- and long-term features of post-MI in human hearts and animal models, and indicates that blunting of this innate immune cardiomyocyte response may offer new hope for the management of HF. Expand
Smad3 Mediates Cardiac Inflammation and Fibrosis in Angiotensin II–Induced Hypertensive Cardiac Remodeling
TLDR
Inactivation of both Smad3 and nuclear factor &kgr;B/p65 signaling pathways was a key mechanism by which Smad 3 KO mice were protected from angiotensin II–mediated hypertensive cardiac remodeling. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 61 REFERENCES
Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now?
  • M. Böhm
  • Medicine
  • The American journal of cardiology
  • 2007
TLDR
Trials that compare telmisartan, ramipril, and their combination in high-risk patients with vascular end-organ damage, should provide important new insights into the benefits of intervention with RAS blockade along the cardiorenovascular continuum. Expand
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
TLDR
In patients with stable coronary heart disease and preserved left ventricular function who are receiving "current standard" therapy and in whom the rate of cardiovascular events is lower than in previous trials of ACE inhibitors, there is no evidence that the addition of an ACE inhibitor provides further benefit in terms of death from cardiovascular causes, myocardial infarction, or coronary revascularization. Expand
Treatment of heart failure with ACE inhibitors and beta-blockers
TLDR
Patients with CHF generally receive a number of other drugs, which include diuretics, digoxin, vasodilators, anti-arrhythmic drugs, anticoagulants, and more recently statins, but none of them has been overall shown to improve outcome. Expand
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study
TLDR
Ramipril significantly reduces the rate of development of heart failure in patients at high risk of cardiovascular events. Expand
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
TLDR
The addition of candesartan to ACE inhibitor and other treatment leads to a further clinically important reduction in relevant cardiovascular events in patients with CHF and reduced left-ventricular ejection fraction. Expand
Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
TLDR
Cedesartan has a moderate impact in preventing admissions for CHF among patients who have heart failure and LVEF higher than 40%. Expand
Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
TLDR
Cedesartan was generally well tolerated and reduced cardiovascular mortality and morbidity in patients with symptomatic chronic heart failure and intolerance to ACE inhibitors. Expand
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
TLDR
Valsartan significantly reduces the combined end point of mortality and morbidity and improves clinical signs and symptoms in patients with heart failure, when added to prescribed therapy, and raises concern about the potential safety of this specific combination. Expand
The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
TLDR
I-PRESERVE is the largest trial in this understudied area and will provide crucial information on the characteristics and course of the syndrome, as well as the efficacy of the angiotensin receptor blocker irbesartan. Expand
The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function.
Angiotensin-converting enzyme inhibitors improve endothelial function, inhibit experimental atherogenesis, and decrease ischemic events. The Quinapril Ischemic Event Trial was designed to test theExpand
...
1
2
3
4
5
...